Alaunos Therapeutics, Inc. (TCRT) stock
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.72+0.06 (+3.61%)
Close on Nov 18, 2026Market cap $4.37MP/E –Yield –
Alaunos Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Alaunos Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.73M. For fiscal 2025 it was -$2.87M. The highest annual figure on record is -$10.00K in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.87M | – |
| FY2024 | Dec 31, 2024 | -$4.97M | – |
| FY2023 | Dec 31, 2023 | -$30.14M | – |
| FY2022 | Dec 31, 2022 | -$29.23M | – |
| FY2021 | Dec 31, 2021 | -$61.47M | – |
| FY2020 | Dec 31, 2020 | -$57.01M | – |
| FY2019 | Dec 31, 2019 | -$40.85M | – |
| FY2018 | Dec 31, 2018 | -$49.46M | – |
| FY2017 | Dec 31, 2017 | -$54.67M | – |
| FY2016 | Dec 31, 2016 | -$58.33M | – |
| FY2015 | Dec 31, 2015 | -$10.00K | – |
| FY2014 | Dec 31, 2014 | -$36.65M | – |
| FY2013 | Dec 31, 2013 | -$59.51M | – |
| FY2012 | Dec 31, 2012 | -$78.83M | – |
| FY2011 | Dec 31, 2011 | -$38.84M | – |
| FY2010 | Dec 31, 2010 | -$19.69M | – |
| FY2009 | Dec 31, 2009 | -$12.29M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$300.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$552.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$844.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$701.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$772.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$592.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$781.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.68M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.13M | – |
| Q1 FY2021 | Jun 30, 2021 | -$36.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.04M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.61M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$10.17M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.96M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.06M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.11M | – |
| Q2 FY2016 | Jun 30, 2016 | -$15.07M | – |
See a number that looks wrong?